Arsenic trioxide with targeted drugs and chemo for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding arsenic trioxide to standard chemotherapy and targeted drugs for children with stage 4 or M neuroblastoma. The goal is to see if this combination helps patients who have advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of neuroblastoma.
- Your cancer is stage 4 or M (has spread to distant parts of the body).
- You are at least 18 months old and not older than 18 years.
- Your parent or guardian must sign a consent form to allow you to participate.
- You have not had chemotherapy or radiation to the abdomen for another type of cancer.
- Your heart, kidneys, and liver are working well enough (doctors will check with tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies an allogeneic (donor) stem cell transplant for children with stage 4 neuroblastoma. It looks at whether the transplant can improve outcomes after chemotherapy and radiotherapy when tumor markers and tiny blood/bone marrow disease are gone.
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.